In an era of ever-increasing healthcare costs, knowledge of cost effectiveness is critical for US physicians, policymakers, and payers alike. Results from a cost-effectiveness study undertaken by investigators from PHAR, LLC and Bristol-Myers Squibb was presented at the 10th International Congress on Drug Therapy in HIV Infection. The model found that patients using atazanavir with ritonavir experience AIDS diagnoses, opportunistic infections, coronary heart disease events, and diarrhea episodes less often than patients using lopinavir in combination with ritonavir.
Archives for November 2010
Studies on Impact of Skeletal-Related Events in Prostate and Breast Cancer Patients Presented at EU ISPOR 2010
Two posters detailing findings from a systematic literature review were presented at the International Society for Pharmacoeconomics 14th Annual European Congress. The systematic review examined the impact of skeletal-related events on pain, quality of life, morbidity, survival, and cost in patients with prostate and breast cancer. The report was created by PHAR, LLC researchers in collaboration with researchers at Bristol-Myers Squibb.